Responses

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    Letter regarding the article "Safety and Efficacy of Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: Preliminary Results of an Open-Label, Long-Term Extension Study"
    • Qiqi Wu, Resident physician Wenzhou Central Hospital

    Dear Editor,

    The recent publication by Brunner et al. [1] on the long-term safety and efficacy of tofacitinib for juvenile idiopathic arthritis (JIA) provides critical insights into the management of this complex condition. Building on their findings, I would like to offer additional perspectives on the implications of these results and suggest areas for future research.

    Firstly, the high incidence of infections observed in the study, particularly upper respiratory tract infections and nasopharyngitis, underscores the need for close monitoring of immunosuppression in pediatric patients. Future research should explore strategies to mitigate these risks, potentially through intermittent dosing schedules or the use of adjunctive therapies that enhance immune function without compromising the efficacy of tofacitinib. Additionally, concerning pediatric patients, it is imperative to assess the impact of long-term tofacitinib treatment on growth and development. Integrating comprehensive evaluations of growth metrics, bone density, and developmental milestones into future studies would ensure that the therapeutic benefits of tofacitinib do not adversely affect physiological development.

    Second, we suggest the authors conduct subgroup analyses based on genetic, demographic, and disease severity indicators so that future research can identify which patients are most likely to benefit from tofacitinib, thereby refining patient selection criteria and enhancing tr...

    Show More
    Conflict of Interest:
    None declared.